Summary
In this study we evaluated 103 patients suffering from acute myeloid leukemia (AML) who did not respond to induction chemotherapy and defined a subgroup of patients with highly refractory disease characterized by a persistence of more than 1G/L blast cells in the peripheral blood between days 12 and 16 of the first induction cycle. Only seven patients (one female, six males) met these criteria. Their median age was 65 years (range 41–82 years). Four had de novo AML and three secondary AML. Cytogenetic analysis was performed in six patients: complex aberrations were detected in four patients and, unexpectedly, normal karyotypes were found in the other two. Analysis of multidrug-resistance factors revealed high co-expression of P-glycoprotein (P-gp) and lung resistance protein (LRP) in all four patients with highly refractory disease tested a finding in only 6% of patients with refractory disease and 3% of patients who achieved complete remission (CR) of disease. Furthermore, patients with highly refractory AML had substantially higher leukocyte counts than patients with refractory AML or CR, although this was not significant statistically.
Overall, patients with highly refractory AML are characterized by a high incidence of complex cytogenetic aberrations and marked expression of drug transporters.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Büchner T (1990) Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicine (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 4: 184–188
Yates J, Glidewell O, Wiemik P, Cooper MR, Steinber D, Dosik H, et al (1982) Cytosine Arabinoside with Daunorubicin or Adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60: 454–462
Fonatsch C, Schaadt M, Kirchner H, Diehl V (1980) A possible correlation between the degree of karyotype aberrations and the rate of sister chromatid exchanges in lymphoma lines. Int J Cancer 26: 749–756
Stollmann B, Fonatsch C, Havers W (1985) Persistent Epstein-Barr virus infection associated with monosomy 7 or chromosome 3 abnormalities in childhood myeloproliferative disorders. Br J Haematol 60: 183–196
Fonatsch C, Streubel B (1998) Classical and molecular cytogenetics. In: Huhn D (ed) New diagnostic methods in oncology and hematology. Springer, Berlin Heidelberg New York Tokyo, pp 113–141
ISCN (1995) An International System for Human Cytogenetic Nomenclature. In: Mitelman F (ed). Karger, Basel
Kottaridis PO, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98: 1752–1759
Filipits M, Jäger U, Simonitsch I, Chizzali-Bonfadin C, Heinzl H, Pirker R (2000) Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas. Clin Cancer Res 6: 3417–3423
Löwenberg B, Dowing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341: 1051–1062
Sperr WR, Hauswirth AW, Wimazal F, Knöbl P, Geissler K, Valent P (2003) Treatment concepts for elderly patients with acute myeloid leukemia. Wien Klin Wochenschr 115: 505–514
Copplestone JA, Prentice AG (1988) Acute myeloblastic leukaemia in the elderly. Leuk Res 12: 617–625
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Harm I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood 92: 2322–2333
Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ (1988) Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 2: 403–412
Mrozek K, Heinonen K, de la Chapelle A, Bloornfeld CD (1997) Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 24: 17–31
Borg AG, Burgess R, Green LM, Scheper RJ, Yin JA (1998) Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 103: 1083–1091
Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, Buccisano F, Masi M, Tribalto M, Amadori S, Papa G (1996) Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 87: 1997–2004
Filipits M, Stranzl T, Pohl G, Heinzl H, Jäger U, Geissler K, Fonatsch C, Haas OA, Lechner K, Pirker R (2000) Drug resistance factors in acute myeloid leukemia: a comparative analysis. Leukemia 14: 68–76
Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jäger U, Geissler K, Lechner K, Pirker R (1998) Expression of lung resistance protein predicts poor outcome in de novo acute myeloid leukemia. Blood 91: 1508–1513
Leith CP, Kopecky KJ, Chen I, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL (1999) Frequency and clinical significance of the expression of the mutidrug resistance proteins MDRIIP-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94: 1086–1099
List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS (1996) Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87: 2464–2469
Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, Lechner K (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83: 708–712
Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ (1988) The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol 6: 232–238
Krykowski E, Polkowska-Kulesza E, Robak T, Matusewicz W, Urbanska-Rys H, Holub A (1987) Analysis of prognostic factors in acute leukemias in adults. Hamatol Bluttransfus 30: 369–372
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Füreder, W., Filipits, M., Sperr, W.R. et al. Highly refractory acute myeloid leukemia. Wien Klin Wochenschr 116, 561–564 (2004). https://doi.org/10.1007/BF03217710
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF03217710